# Optimization of Golimumab Treatment in Ulcerative Colitis

> **NCT03669029** · PHASE4 · UNKNOWN · sponsor: **Hospital de Manises** · enrollment: 50 (estimated)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg
- **DRUG:** Golimumab treatment optimization.

## Key facts

- **NCT ID:** NCT03669029
- **Lead sponsor:** Hospital de Manises
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669029, "Optimization of Golimumab Treatment in Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03669029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*